奥拉单抗（Lartruvo）：软组织肉瘤的创新疗法。
Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma.
作者信息
Penniman Lindsey, Parmar Sapna, Patel Khilna
出版信息
P T. 2018 May;43(5):267-270.
Abstract
Olaratumab (Lartruvo): an innovative treatment for soft tissue sarcoma.
摘要
奥拉单抗（Lartruvo）：一种用于软组织肉瘤的创新疗法。
相似文献
1
Olaratumab (Lartruvo): An Innovative Treatment for Soft Tissue Sarcoma.奥拉单抗（Lartruvo）：软组织肉瘤的创新疗法。
P T. 2018 May;43(5):267-270.
2
Olaratumab (Lartruvo) for soft-tissue sarcoma.奥拉单抗（Lartruvo）用于治疗软组织肉瘤。
Med Lett Drugs Ther. 2017 Aug 14;59(1527):e138-e139.
3
Olaratumab's failure in soft tissue sarcoma.奥拉单抗在软组织肉瘤治疗中的失败。
Rare Tumors. 2021 Jul 18;13:20363613211034115. doi: 10.1177/20363613211034115. eCollection 2021.
4
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.奥拉单抗联合多柔比星治疗晚期软组织肉瘤：英国国家卫生与保健优化研究所单一技术评估中证据审查组的观点。
Pharmacoeconomics. 2018 Jan;36(1):39-49. doi: 10.1007/s40273-017-0568-3.
5
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.奥拉单抗与多柔比星联合治疗与多柔比星单药治疗软组织肉瘤的疗效比较：一项开放标签的1b期和随机2期试验。
Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9.
6
Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.奥拉单抗：一种用于晚期软组织肉瘤的新型血小板衍生生长因子受体α抑制剂。
Ann Pharmacother. 2017 Dec;51(12):1090-1098. doi: 10.1177/1060028017723935. Epub 2017 Aug 4.
7
Olaratumab for advanced soft tissue sarcoma.奥拉单抗用于治疗晚期软组织肉瘤。
Expert Rev Clin Pharmacol. 2017 Jul;10(7):699-705. doi: 10.1080/17512433.2017.1324295. Epub 2017 May 5.
8
Olaratumab for the treatment of advanced soft tissue sarcoma.奥拉单抗用于治疗晚期软组织肉瘤。
Expert Rev Anticancer Ther. 2017 Oct;17(10):883-887. doi: 10.1080/14737140.2017.1374857. Epub 2017 Sep 8.
9
Olaratumab in soft tissue sarcoma - Current status and future perspectives.奥拉单抗治疗软组织肉瘤的现状与未来展望。
Eur J Cancer. 2018 Mar;92:33-39. doi: 10.1016/j.ejca.2017.12.026. Epub 2018 Feb 3.
10
Olaratumab for the treatment of soft-tissue sarcoma.奥拉单抗治疗软组织肉瘤。
Future Oncol. 2017 Oct;13(24):2151-2157. doi: 10.2217/fon-2017-0210. Epub 2017 Jul 26.
引用本文的文献
1
Exploring potential roles of long non-coding RNAs in cancer immunotherapy: a comprehensive review.探索长链非编码 RNA 在癌症免疫治疗中的潜在作用：全面综述。
Front Immunol. 2024 Aug 27;15:1446937. doi: 10.3389/fimmu.2024.1446937. eCollection 2024.
2
Updates on the mechanisms of toxicities associated with monoclonal antibodies targeting growth factor signaling and immune cells in cancer.癌症中靶向生长因子信号传导和免疫细胞的单克隆抗体相关毒性机制的最新进展。
Toxicol Res. 2024 Apr 22;40(3):335-348. doi: 10.1007/s43188-024-00233-4. eCollection 2024 Jul.
3
Olaratumab's failure in soft tissue sarcoma.奥拉单抗在软组织肉瘤治疗中的失败。
Rare Tumors. 2021 Jul 18;13:20363613211034115. doi: 10.1177/20363613211034115. eCollection 2021.
4
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion.癌症相关成纤维细胞：肿瘤免疫逃逸的帮凶。
Cancers (Basel). 2020 Oct 14;12(10):2969. doi: 10.3390/cancers12102969.
5
A Multi-Modality Treatment of Retroperitoneal De-Differentiated Liposarcoma.一种腹膜后去分化脂肪肉瘤的多模态治疗方法。
Am J Case Rep. 2020 Mar 2;21:e919245. doi: 10.12659/AJCR.919245.
本文引用的文献
1
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
2
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.PICASSO III 研究：多柔比星联合或不联合帕利夫司他治疗转移性软组织肉瘤的 III 期、安慰剂对照研究。
J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.
3
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.奥拉单抗与多柔比星联合治疗与多柔比星单药治疗软组织肉瘤的疗效比较：一项开放标签的1b期和随机2期试验。
Lancet. 2016 Jul 30;388(10043):488-97. doi: 10.1016/S0140-6736(16)30587-6. Epub 2016 Jun 9.
4
Phase I study of olaratumab in Japanese patients with advanced solid tumors.奥拉单抗在日本晚期实体瘤患者中的 I 期研究。
Cancer Sci. 2014 Jul;105(7):862-9. doi: 10.1111/cas.12444. Epub 2014 Jun 27.
5
Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 cases.成人软组织肉瘤中某些既定风险因素的发生率：一项对658例病例的前瞻性描述性研究。
Sarcoma. 2008;2008:459386. doi: 10.1155/2008/459386.
6
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.多柔比星与CYVADIC方案及多柔比星联合异环磷酰胺用于晚期软组织肉瘤一线治疗的比较：欧洲癌症研究与治疗组织软组织和骨肉瘤组的一项随机研究
J Clin Oncol. 1995 Jul;13(7):1537-45. doi: 10.1200/JCO.1995.13.7.1537.
7
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
Cancer. 1990 Sep 1;66(5):862-7. doi: 10.1002/1097-0142(19900901)66:5<862::aid-cncr2820660509>3.0.co;2-r.
Zotero 插件